Parkev Tatevosian, CFA 对 $UNH 的判断变化

频道资料 →频道引用的来源:Barclays analyst Dan Levy、Meta management and CEO Mark Zuckerberg、Nike management共 2 条

Parkev Tatevosian, CFA 自 2026-09-24 起在 2 个视频里谈过 $UNH,最近一次(2026-11-11)为看涨。

2026-11-11看涨
《Is it Too Late to Buy UnitedHealth Stock? | UNH Stock Analysis》
AI 摘要 · UNH 仍是买入机会:公司正从 2025 年的成本定价失误中恢复,长期 EPS 增长预期已回升至 14.2% 以上,落在管理层 13-16% 的目标区间内;同时高成本仍在持续,退出市场和提价正在减少客户。当前远期市盈率为 17,低于 2025 年前的水平并接近长期 EPS 增速,DCF 估值为 532 美元,而现价为 396 美元,因此看起来被低估;尽管没有哪只股票是无风险的,但风险回报比值得承担。

UnitedHealth Group 正在从2025年所面临的巨大困难中恢复过来。要记得,在那一年,公司低估了服务客户的成本,因此没有为保单合理定价,导致公司的盈利能力和自由现金流大幅下降。

UnitedHealth Group is recovering from the enormous difficulties it faced in 2025. Remember that in that year, the company underestimated the cost of serving its customers and therefore did not price its policies appropriately, resulting in a significant decrease in the company's profitability and free cash flow .

2026-09-24看涨
《Is UnitedHealth Stock an Undervalued Stock to Buy Right Now? | UNH Stock Analysis》
AI 摘要 · UNH 值得买入;管理层的利润率复苏以及上调的自由现金流预期,支撑未来 12-18 个月约 40% 的上行空间。

2025年对UnitedHealth来说是极为糟糕的一年,因为公司管理层低估了客户服务的成本。在年底以及2026年初,管理层做出了若干调整,以适应当前的情况。

2025 was a very bad year for UnitedHealth, as the company's management team underestimated the cost of customer service. At the end of the year and the beginning of 2026, the management team made several adjustments to comply with current conditions.

作为分析师,我们原本预期这些调整会带来某些结果。结果比预期更好。今天,我已上调了对该公司自由现金流的预估,以适应这些更好的情况。

As analysts, we were expecting certain results as a result of those adjustments. The results turned out to be better than expected. Today, I have raised my estimates for the company's free cash flow to adapt to these better conditions.